Arax Advisory Partners
GLSI icon

Arax Advisory Partners’s Greenwich LifeSciences GLSI Stock Holding History

Arax Advisory Partners’s Portfolio GLSI Stock Details GLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$633 Buy
27
+26
+2,600% +$633 ﹤0.01% 4991
2026
Q1 		$24 Buy
+1
New +$26 ﹤0.01% 3700
2025
Q4 		– Sell
-123
Closed -$1.22K – 4265
2025
Q3 		$1.22K Buy
+123
New +$1.39K ﹤0.01% 3211

Other funds holding GLSI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arax Advisory Partners's GLSI Position: Q2 2026 in Review

Arax Advisory Partners increased its Greenwich LifeSciences (GLSI) stake by 2,600% in Q2 2026, buying an estimated $633 and bringing the position to 27 shares worth $633. The position accounts for ﹤0.01% of the portfolio, ranked #4991.

Arax Advisory Partners first reported a position in GLSI in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.22K in Q3 2025. 57 funds tracked by Wall St. Rank hold GLSI as of Q2 2026.

  • Arax Advisory Partners held 27 shares of Greenwich LifeSciences worth $633 as of Q2 2026.
  • Arax Advisory Partners bought 26 Greenwich LifeSciences shares in Q2 2026, an estimated $633.
  • Greenwich LifeSciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4991 holding.
  • Arax Advisory Partners first reported a position in Greenwich LifeSciences in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's Greenwich LifeSciences position peaked at $1.22K in Q3 2025.
  • 57 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.